Clinical potential of mesenchymal stem/stromal cell-derived extracellular vesicles
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Within the last two decades mesenchymal stem/stromal cells (MSCs) emerged after hematopoietic stem cells as the second most investigated and applied somatic stem cell entity so far. MSCs mediate immunosuppressive as well as pro-regenerative activities. Against the initial assumption, MSCs may not primarily exert their therapeutic functions in a cellular but rather in a paracrine manner. Here, extracellular vesicles (EVs), such as exosomes and microvesicles, have been identified as major mediators of these paracrine effects. Meanwhile, MSC-EVs have been applied to an increasing amount of different animal models and were tested in a patient suffering from steroid-refractory acute graft-versus-host disease (acute GvHD) as well as in a patient cohort with chronic kidney disease. So far, the MSC-EV administration appears to be safe in humans and all tested animal models. Improvements were reported in all settings. Thus, MSC-EVs appear as promising novel therapeutic agents which might help to improve disease associated symptoms in millions of patients. Here, we review some of the milestones in the field, briefly discuss challenges and highlight clinical aspects of acute GvHD and its treatment with MSCs and MSC-EVs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Extracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099 · cited 2×
“Microvesicles derive as bud offs from the plasma membrane and have sizes between 100 and 1,000 nm (64).”
BackgroundBiological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926
Self-citationIsolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
B lymphocytes secrete antigen-presenting vesicles.
Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J., & Geuze, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1161 · Cited by 3,546 · cited 1×
“The first experimental evidence that EVs act as signaling mediators in immune biological processes was provided by Raposo and colleagues in 1996 (72).”
BackgroundDi Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Johnstone, R. M., Adam, M., Hammond, J. R., Orr, L., & Turbide, C. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48095-7 · Cited by 2,931 · cited 1×
“Upon studying transferrin trafficking it was observed that against the initial hypothesis a proportion of MVBs do not fuse with lysosomes to degrade their inner cargo but with the plasma membrane to release their cargo including the ILVs into the extracellular environment (65-67).”
BackgroundLe Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Németh, K., Leelahavanichkul, A., Yuen, P. S. T., Mayer, B., Parmelee, A., Doi, K., Robey, P. G., Leelahavanichkul, K., Koller, B. H., Brown, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1905 · Cited by 2,364 · cited 1×
“Furthermore, MSCs were found to modulate the polarization of pro-inflammatory M1 to anti-inflammatory M2 macrophages and to inhibit NK cell activities (25-28).”
BackgroundRegulation of immune responses by extracellular vesicles
Robbins, P. D., & Morelli, A. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3622 · Cited by 2,260 · cited 1×
“Since then, EVs were found to mediate the interaction between various immune cell types and also between tumor and immune cells (68,73).”
Background
Cited by
Therapeutically harnessing extracellular vesicles
Cheng, L., & Hill, A. F. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00410-w · Cited by 737
Witwer, K. W., Van Balkom, B. W. M., Bruno, S., Choo, A., Dominici, M., Gimona, M., Hill, A. F., De Kleijn, D., Koh, M., Lai, R. C., et al. (2019) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1609206 · Cited by 671
Self-citationMSC exosome works through a protein-based mechanism of action
Toh, W. S., Lai, R. C., Zhang, B., & Lim, S. K. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180079 · Cited by 394
Approaches to surface engineering of extracellular vesicles
Richter, M., Vader, P., & Fuhrmann, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.020 · Cited by 258
Humbert, P., Brennan, M. Á., Davison, N., Rosset, P., Trichet, V., Blanchard, F., & Layrolle, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00663 · Cited by 119
Bari, E., Ferrarotti, I., Di Silvestre, D., Grisoli, P., Barzon, V., Balderacchi, A., Torre, M. L., Rossi, R., Mauri, P., Corsico, A. G., et al. (2019) · Cells · doi:10.3390/cells8090965 · Cited by 70
Azizsoltani, A., Hatami, B., Zali, M. R., Mahdavi, V., Baghaei, K., & Alizadeh, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115777 · Cited by 40
Metadata
- Authors
- Giebel, B., Kordelas, L., & Börger, V.
- Venue
- Stem Cell Investigation
- Publisher
- AME Publishing Company
- Published
- 2017-10-24
- Volume
- 4
- Issue
- 10
- Pages
- 84-84
- ISSN
- 2306-9759 (ISSN-L)
- 2313-0792
- OpenAlex
- W2766582147
- Cited by
- 157
- References
- 16
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.